Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Posts Quarterly Earnings Results, Beats Expectations By $1.01 EPS

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) announced its earnings results on Monday. The biotechnology company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.97) by $1.01, FiscalAI reports. The firm had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $7.29 million.

Lakefront Biotherapeutics American Depositary Shares Price Performance

Lakefront Biotherapeutics American Depositary Shares stock opened at $26.91 on Tuesday. The firm has a market capitalization of $1.77 billion, a P/E ratio of -19.09 and a beta of 0.27. Lakefront Biotherapeutics American Depositary Shares has a one year low of $25.68 and a one year high of $37.78. The business has a fifty day moving average price of $28.65 and a 200-day moving average price of $30.11.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LKFT shares. Morgan Stanley initiated coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Friday, July 10th. They issued an “equal weight” rating and a $30.00 price objective for the company. Wall Street Zen downgraded Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings cut Lakefront Biotherapeutics American Depositary Shares from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 4th. Finally, Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, Lakefront Biotherapeutics American Depositary Shares has a consensus rating of “Hold” and an average target price of $34.33.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Aquatic Capital Management LLC lifted its stake in Lakefront Biotherapeutics American Depositary Shares by 63.6% in the 3rd quarter. Aquatic Capital Management LLC now owns 17,516 shares of the biotechnology company’s stock worth $607,000 after purchasing an additional 6,807 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Lakefront Biotherapeutics American Depositary Shares by 81.0% in the third quarter. BNP Paribas Financial Markets now owns 11,854 shares of the biotechnology company’s stock worth $411,000 after buying an additional 5,305 shares in the last quarter. Orion Porfolio Solutions LLC bought a new stake in Lakefront Biotherapeutics American Depositary Shares during the third quarter valued at $252,000. Headlands Technologies LLC purchased a new position in Lakefront Biotherapeutics American Depositary Shares during the second quarter worth about $223,000. Finally, Engineers Gate Manager LP purchased a new position in Lakefront Biotherapeutics American Depositary Shares during the second quarter worth about $560,000. Institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.